x

News Summary: Merck settles cholesterol drug suits

Print Page Updated: 10:50:25 PM, Thu 14 February 2013
SUIT SETTLEMENT: Drugmaker Merck agreed to pay $688 million to settle two investor lawsuits over a long delay in releasing results of a study meant to show its blockbuster cholesterol drugs reduced plaque buildup in arteries. But it found that Merck's Zetia and Vytorin were no better than a cheap generic pill.

MERCK RESPONSE: Merck admits no wrongdoing and said it was in its best interest to end the suits.

FINANCIAL IMPACT: Merck took a $493 million charge and restated its 2012 financial results, reducing earnings per share by 16 cents each for the fourth quarter and the full year.

Tags: merck, cents, health, quarter, news summary, finance, financial results, study, arteries, earnings, suit, wrongdoing, charge, drug, hydrogen, merck settles cholesterol, drugmaker merck, blockbuster cholesterol drugs, merck response, cheap generic pill, drug suits, plaque buildup, investor lawsuits, suit settlement, long delay, financial impact, zetia, schering-plough, ezetimibe/simvastatin, american record labels

Close
Loading

News Headlines.com

Close
Contact Us
Send Feedback X